Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.